Latest News and Press Releases

Ad-hoc-Mitteilung gemäss Art. 53 KR Liquide Mittel in Höhe von CHF 8,0 Millionen (Stand: 30. Juni 2021)Nettoumsatz CHF 4,5 Millionen (H1-2020: CHF 7,8 Millionen)Netto Halbjahresergebnis von...

Ad hoc announcement pursuant to Art. 53 LR Cash and cash equivalents of CHF 8.0 million (as of June 30, 2021)Net revenue CHF 4.5 million (H1-2020: CHF 7.8 million)Net result for period of...

Ad hoc-Mitteilung gemäss Art. 53 KR Pratteln, Schweiz, 1. Oktober 2021 -SIX Exchange Regulation hat Santhera gestattet, den Zwischenberichts für die sechs Monate bis zum 30. Juni 2021 spätestens am...

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, October 1, 2021 : SIX Exchange Regulation has permitted Santhera to publish its interim report for the six-month period ended...

Rockville, MD, USA, und Pratteln, Schweiz, 27. September 2022 – ReveraGen Biopharma und Santhera Pharmaceuticals (SIX: SANN) geben bekannt, dass ReveraGen von der FDA im Rahmen ihres Förderprogramms...

Rockville, MD, USA, and Pratteln, Switzerland, September 27, 2021 – ReveraGen Biopharma and Santhera Pharmaceuticals (SIX: SANN) announce that ReveraGen has received a USD 1.2 million grant from the...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc-Mitteilung gemäss Art. 53 KR Pratteln, Schweiz,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland,...

Pratteln, Schweiz, und Rockville, MD, USA, 23. September 2021 – Santhera Pharmaceuticals (SIX: SANN) und ReveraGen BioPharma, Inc. (US: privat) geben bekannt, dass sie auf der bevorstehenden World...

Pratteln, Switzerland, and Rockville, MD, USA, September 23, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc (US: private) announce presentations of the positive topline...